
Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030
Description
Biosimulation Market Size, Share & Trends Analysis Report By Product (Software, Services), By Application, Therapeutic Area, By Deployment Model, By Pricing Model, By End Use, By Region, And Segment Forecasts, 2025 - 2030
Medical Device Complaint Management Market Growth & Trends
The global medical device complaint management market size is estimated to reach USD 13.33 billion by 2030, registering a CAGR of 8.79% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing utilization of software aiding in the overall complaint management process is expected to increase the market growth. The growing adoption of the digital system over paper-based work for tracking medical complaints is further boosting the market growth.
The medical device industry is highly regulated and inadequate product complaint handling accounts for a large percentage of FDA inspection findings. The complaints create severe reputational and brand risks and they need to be officially documented, inspected, tracked, and closed. Complaints may be minor, but they may also include a potential risk to the safety of the patient or product function or quality, which could cause damage to the company. Thus, it is important that all the complaints are correctly recorded in automated and integrated complaint management solutions to ensure that they are accurately investigated and addressed.
An increase in the demand for medical complaint management solutions has been registered over the past few years owing to the streamlined process. Incidents are recorded and the data automatically drives the investigation and resolution workflow. Companies are attaining complete medical documentation with minimal errors along with reduced turnaround time on the account of fact that complaint management solutions offer advanced analytics and reporting tools for augmented management oversight.
Moreover, the majority of companies are coming up with mobile app solutions to manage customer medical complaints. For instance, Intellect and Beckman Coulter in collaboration with Impiger technologies provide a mobile app platform on Google Play Store and the App Store to their customers, which enables them to register complaints, escalate tickets, and generate an inquiry. In addition, regulators are gradually focusing on handling customer complaints, the safety of the product, and device vigilance in both developed and emerging economies.
Medical Device Complaint Management Market Report Highlights
- The market is expected to grow owing to an increase in the adoption of automated complaint filing systems over a paper-based system.
- By service type, the product surveillance and regulatory compliance segment emerged as the largest segment in 2024, owing to the fact that regulatory agencies and medical device users are increasingly focusing on product surveillance in order to avoid failure of the medical devices.
- North America dominated the market in 2024, owing to the presence of regulatory requirements in the region, coupled with the high incidence of medical device complaints witnessed over the past few years.
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Application Segment
- 1.2.3. Therapeutic Area Segment
- 1.2.4. Deployment Model Segment
- 1.2.5. Pricing Model Segment
- 1.2.6. End Use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
- Chapter 3. Biosimulation Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of chronic diseases
- 3.2.1.2. Growing demand for personalized medicine
- 3.2.1.3. Technological advancements
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost associated with biosimulation technology and software
- 3.2.2.2. Stringent regulatory requirements
- 3.3. Biosimulation Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.2.4. Environmental Landscape
- 3.3.2.5. Legal Landscape
- 3.3.2.6. Social Landscape
- 3.4. COVID-19 Impact Analysis
- Chapter 4. Biosimulation Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Biosimulation Market Product Movement Analysis
- 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
- 4.4. Software
- 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.2. Molecular Modeling & Simulation Software
- 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.3. Clinical Trial Design Software
- 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.4. PK/PD Modeling and Simulation Software
- 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.5. Pbpk Modeling and Simulation Software
- 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.6. Toxicity Prediction Software
- 4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.4.7. Other Software
- 4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5. Services
- 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5.2. Contract Services
- 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5.3. Consulting
- 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 4.5.4. Other (Implementation, Training, & Support, etc.)
- 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Biosimulation Market Application Movement Analysis
- 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
- 5.4. Drug Discovery & Development
- 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.5. Disease Modeling
- 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 5.6. Other (Precision Medicine, Toxicology, etc.)
- 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
- 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
- 6.4. Oncology
- 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.5. Cardiovascular Disease
- 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.6. Infectious Disease
- 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.7. Neurological Disorders
- 6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 6.8. Others
- 6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Biosimulation Market Deployment Model Movement Analysis
- 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
- 7.4. Cloud-based
- 7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.5. On-premises
- 7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 7.6. Hybrid Model
- 7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Biosimulation Market Pricing Model Movement Analysis
- 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
- 8.4. License-based Model
- 8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 8.5. Subscription-based Model
- 8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 8.6. Service-based Model
- 8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 8.7. Pay Per Use Model
- 8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis
- 9.1. Segment Dashboard
- 9.2. Global Biosimulation Market End Use Movement Analysis
- 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
- 9.4. Life Science Companies
- 9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.4.2. Pharmaceutical Companies
- 9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.4.3. Biopharma Companies
- 9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.4.4. Medical Device Companies
- 9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.4.5. CROs/CDMOs
- 9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.5. Academic Research Institutions
- 9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- 9.6. Others (Regulatory Authorities, etc.)
- 9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis
- 10.1. Regional Market Share Analysis, 2024 & 2030
- 10.2. Regional Market Dashboard
- 10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
- 10.4. North America
- 10.4.1. U.S.
- 10.4.1.1. Key country dynamics
- 10.4.1.2. Regulatory framework
- 10.4.1.3. Competitive scenario
- 10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
- 10.4.2. Canada
- 10.4.2.1. Key country dynamics
- 10.4.2.2. Regulatory framework
- 10.4.2.3. Competitive scenario
- 10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
- 10.4.3. Mexico
- 10.4.3.1. Key country dynamics
- 10.4.3.2. Regulatory framework
- 10.4.3.3. Competitive scenario
- 10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5. Europe
- 10.5.1. UK
- 10.5.1.1. Key country dynamics
- 10.5.1.2. Regulatory framework
- 10.5.1.3. Competitive scenario
- 10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.2. Germany
- 10.5.2.1. Key country dynamics
- 10.5.2.2. Regulatory framework
- 10.5.2.3. Competitive scenario
- 10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.3. France
- 10.5.3.1. Key country dynamics
- 10.5.3.2. Regulatory framework
- 10.5.3.3. Competitive scenario
- 10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.4. Italy
- 10.5.4.1. Key country dynamics
- 10.5.4.2. Regulatory framework
- 10.5.4.3. Competitive scenario
- 10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.5. Spain
- 10.5.5.1. Key country dynamics
- 10.5.5.2. Regulatory framework
- 10.5.5.3. Competitive scenario
- 10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.6. Norway
- 10.5.6.1. Key country dynamics
- 10.5.6.2. Regulatory framework
- 10.5.6.3. Competitive scenario
- 10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.7. Sweden
- 10.5.7.1. Key country dynamics
- 10.5.7.2. Regulatory framework
- 10.5.7.3. Competitive scenario
- 10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
- 10.5.8. Denmark
- 10.5.8.1. Key country dynamics
- 10.5.8.2. Regulatory framework
- 10.5.8.3. Competitive scenario
- 10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6. Asia Pacific
- 10.6.1. Japan
- 10.6.1.1. Key country dynamics
- 10.6.1.2. Regulatory framework
- 10.6.1.3. Competitive scenario
- 10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6.2. China
- 10.6.2.1. Key country dynamics
- 10.6.2.2. Regulatory framework
- 10.6.2.3. Competitive scenario
- 10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6.3. India
- 10.6.3.1. Key country dynamics
- 10.6.3.2. Regulatory framework
- 10.6.3.3. Competitive scenario
- 10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6.4. Australia
- 10.6.4.1. Key country dynamics
- 10.6.4.2. Regulatory framework
- 10.6.4.3. Competitive scenario
- 10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6.5. South Korea
- 10.6.5.1. Key country dynamics
- 10.6.5.2. Regulatory framework
- 10.6.5.3. Competitive scenario
- 10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
- 10.6.6. Thailand
- 10.6.6.1. Key country dynamics
- 10.6.6.2. Regulatory framework
- 10.6.6.3. Competitive scenario
- 10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
- 10.7. Latin America
- 10.7.1. Brazil
- 10.7.1.1. Key country dynamics
- 10.7.1.2. Regulatory framework
- 10.7.1.3. Competitive scenario
- 10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
- 10.7.2. Argentina
- 10.7.2.1. Key country dynamics
- 10.7.2.2. Regulatory framework
- 10.7.2.3. Competitive scenario
- 10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
- 10.8. MEA
- 10.8.1. South Africa
- 10.8.1.1. Key country dynamics
- 10.8.1.2. Regulatory framework
- 10.8.1.3. Competitive scenario
- 10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
- 10.8.2. Saudi Arabia
- 10.8.2.1. Key country dynamics
- 10.8.2.2. Regulatory framework
- 10.8.2.3. Competitive scenario
- 10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
- 10.8.3. UAE
- 10.8.3.1. Key country dynamics
- 10.8.3.2. Regulatory framework
- 10.8.3.3. Competitive scenario
- 10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
- 10.8.4. Kuwait
- 10.8.4.1. Key country dynamics
- 10.8.4.2. Regulatory framework
- 10.8.4.3. Competitive scenario
- 10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
- Chapter 11. Competitive Landscape
- 11.1. Company/Competition Categorization
- 11.2. Strategy Mapping
- 11.3. Company Market Position/Share Analysis, 2024
- 11.4. Company Profiles/Listing
- 11.4.1. Certara, USA
- 11.4.1.1. Company overview
- 11.4.1.2. Financial performance
- 11.4.1.3. Product benchmarking
- 11.4.1.4. Strategic initiatives
- 11.4.2. Dassault Systèmes
- 11.4.2.1. Company overview
- 11.4.2.2. Financial performance
- 11.4.2.3. Product benchmarking
- 11.4.2.4. Strategic initiatives
- 11.4.3. Advanced Chemistry Development
- 11.4.3.1. Company overview
- 11.4.3.2. Financial performance
- 11.4.3.3. Product benchmarking
- 11.4.3.4. Strategic initiatives
- 11.4.4. Simulation Plus
- 11.4.4.1. Company overview
- 11.4.4.2. Financial performance
- 11.4.4.3. Product benchmarking
- 11.4.4.4. Strategic initiatives
- 11.4.5. Schrodinger, Inc.
- 11.4.5.1. Company overview
- 11.4.5.2. Financial performance
- 11.4.5.3. Product benchmarking
- 11.4.5.4. Strategic initiatives
- 11.4.6. Chemical Computing Group ULC
- 11.4.6.1. Company overview
- 11.4.6.2. Financial performance
- 11.4.6.3. Product benchmarking
- 11.4.6.4. Strategic initiatives
- 11.4.7. Physiomics Plc
- 11.4.7.1. Company overview
- 11.4.7.2. Financial performance
- 11.4.7.3. Product benchmarking
- 11.4.7.4. Strategic initiatives
- 11.4.8. Rosa & Co. LLC
- 11.4.8.1. Company overview
- 11.4.8.2. Financial performance
- 11.4.8.3. Product benchmarking
- 11.4.8.4. Strategic initiatives
- 11.4.9. BioSimulation Consulting Inc.
- 11.4.9.1. Company overview
- 11.4.9.2. Financial performance
- 11.4.9.3. Product benchmarking
- 11.4.9.4. Strategic initiatives
- 11.4.10. Genedata AG
- 11.4.10.1. Company overview
- 11.4.10.2. Financial performance
- 11.4.10.3. Product benchmarking
- 11.4.10.4. Strategic initiatives
- 11.4.11. Instem Group of Companies
- 11.4.11.1. Company overview
- 11.4.11.2. Financial performance
- 11.4.11.3. Product benchmarking
- 11.4.11.4. Strategic initiatives
- 11.4.12. PPD, Inc.
- 11.4.12.1. Company overview
- 11.4.12.2. Financial performance
- 11.4.12.3. Product benchmarking
- 11.4.12.4. Strategic initiatives
- 11.4.13. Yokogawa Insilico Biotechnology GmbH
- 11.4.13.1. Company overview
- 11.4.13.2. Financial performance
- 11.4.13.3. Product benchmarking
- 11.4.13.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.